GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 144 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 GlaxoSmithKline Research & Development Ltd, U.K. 10.34 41.78 GlaxoSmithKline Services Unlimited, U.K. 4,59.07 4,11.65 Glaxo Operations UK Limited, U.K 4,59.91 4,57.88 GlaxoSmithKline Trading Services Limited, Ireland 2,97.64 2,48.65 GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria - 36.12 GlaxoSmithKline Pte Limited, Singapore - 36.05 (d) Expenses recharged by other companies: GlaxoSmithKline Consumer Healthcare Limited, India - 72,03.67 GlaxoSmithKline Services Unlimited, U.K. 1,19.84 1,23.30 SmithKline Beecham Pharmaceuticals U.S.A 97.50 - SmithKline Beecham Limited, U.K. 30.22 15.95 GlaxoSmithKline Pte Limited, Singapore 49.56 - GlaxoSmithKline Asia Private Limited, India 93,87.51 1,24.54 (e) Manufacturing charges recovered: GlaxoSmithKline Asia Private Limited, India 4,31.95 13,84.54 Biddle Sawyer Limited 4,65.95 - (f) Clinical research and data management recoveries: GlaxoSmithKline Biologicals S.A., Belgium 7,84.03 7,48.60 GlaxoSmithKline Research & Development Ltd, U.K. 1,00.44 1,49.66 (g) Sale of laptops: GlaxoSmithKline Asia Private Limited, India - 28.56 (h) Liabilities written back: GlaxoSmithKline South Africa (Pty) Ltd, South Africa 77.24 - (i) Employee benefit liabilities transferred to a related party: GlaxoSmithKline Asia Private Limited, India 19.86 13.51 ( ` in lakhs) As at March 31, 2021 (j) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 1,57.35 Biddle Sawyer Limited, India 4,04.06 GlaxoSmithKline Export Limited, U.K. 19.17 GlaxoSmithKline Research & Development Ltd, U.K. 15.70 GlaxoSmithKline Services Unlimited, U.K. 66.46 Glaxo Operations UK Limited, U.K. 1,32.05 GSK India Global Services Private Limited 2,83.84